TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01267734
Drug: Triple anti-platelet therapy (TAT)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
Study: NCT02603614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT00679315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.
Study: NCT03116893
Drug: BI 685509 After Standardised Breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat high calorie breakfast
Study: NCT01125683
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral single and multiple dose
Study: NCT01125683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral and single dose
Study: NCT00292266
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
Study: NCT00292266
Drug: Avonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
Study: NCT01679860
Drug: Clin B (CHOP- CAMPATH) Chemo-immunotherapy
Normalized name: DISPENSING PIN,CHEMO B BRAUN #412014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.
Study: NCT01083576
Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application to CL lesions once daily for 20 days
Study: NCT01083576
Drug: Paromomycin Alone Cream (15% paromomycin topical cream)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application to CL lesions once daily for 20 days
Study: NCT02459353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04002544
Drug: NTG patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
Study: NCT04043026
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any statin therapy
Study: NCT00482092
Drug: Prochymal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochymal® IV infusion
Study: NCT00482092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochymal® Placebo-matching IV infusion
Study: NCT00694993
Drug: GSK1004723
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Study: NCT00694993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Study: NCT00486200
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT00486200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo.
Study: NCT03230097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
Study: NCT00577681
Drug: Antiretroviral Therapy (ART)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
Study: NCT00509015
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of lactose tablets (160mg) albochin
Study: NCT01312272
Drug: Inactive placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
Study: NCT03081169
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The same drugs and dosages will be used in both groups, with only the timing being different
Study: NCT04443608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
Study: NCT02198352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03374397
Drug: Surgiguard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
Study: NCT00119626
Drug: NXY-059
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01292616
Drug: therapy with disease-modifying anti rheumatic drugs (DMARD)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD drug and dosage is chosen by the treating physician without restriction by the study
Study: NCT01013376
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT01084369
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.
Study: NCT00428311
Drug: Ethynyl-estradiol plus cyproterone acetate
Normalized name: Ethynyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03198117
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: a Chinese traditional medicine
Study: NCT03782792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT02073552
Drug: Macrogol 3350 plus ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
Study: NCT01180062
Drug: Arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
Study: NCT01280175
Drug: pMDI standard actuator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01201018
Drug: Oshadi D, Oshadi R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02866552
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02706691
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth (oral)
Study: NCT01427686
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
Study: NCT00772291
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug during 8 weeks
Study: NCT00217295
Drug: Avonex and Topamax
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619423
Drug: Placebo (0,9% NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Study: NCT04022993
Drug: Lantus Solostar, 100 Units/mL Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Study: NCT04022993
Drug: Insulin RinGlar, 100 Units/mL Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Study: NCT00113984
Drug: MDX-010
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04343547
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily single dose
Study: NCT04343547
Drug: DWC202001+DWC202002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Study: NCT04343547
Drug: DWP16001+DWC202001+DWC202002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Study: NCT02521610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Study: NCT02521610
Drug: RG7625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Study: NCT01007097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Study: NCT04343963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet P.O. once per day for 14 days
Study: NCT03925974
Drug: KN026 10 mg/kg QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg QW as safety run-in dosage
Study: NCT03925974
Drug: KN026 20 mg/kg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg Q2W as target dosage
Study: NCT03925974
Drug: KN026 30 mg/kg Q3W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg Q3W as another target dosage
Study: NCT00851747
Drug: Phosphatidylcholine Deoxycholate
Normalized name: deoxycholate
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study: NCT01352858
Drug: TolDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
Study: NCT01352858
Drug: Arthroscopy & saline irrigation alone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04176757
Drug: ZN-c5
Normalized name: dipentaerythrityl hexa C5-10 acid esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c5 study drug to be administered orally daily
Study: NCT04412824
Drug: Intravenous blood draw
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
Study: NCT01854710
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staccato placebo via inhalation x 2 at 2 hours apart
Study: NCT01854710
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule identical in appearance to moxifloxacin
Study: NCT03951571
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Study: NCT00064116
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
Study: NCT02407353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo which will be dosed as oral suspension, single doses to match PF-06648671
Study: NCT00967135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo twice daily for 5 consecutive days.
Study: NCT04149691
Drug: CPL304110
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
Study: NCT00834444
Drug: Famvir® 500 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg, single-dose fasting
Study: NCT04418167
Drug: JSI-1187
Approvals — FDA: no, EMA: no, PMDA: no
Description: JSI-1187 capsules for oral administration
Study: NCT02890069
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02817100
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
Study: NCT02890069
Drug: QBM076
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890069
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01496495
Drug: ARRY-614, p38/Tie2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT02817100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
Study: NCT01614223
Drug: Corticosteroid (celestone) injection
Normalized name: Celestone Soluspan Injectable Product
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
Study: NCT02936830
Drug: 15% Nanohydroxyapetite paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
Study: NCT02300688
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 time administration of the test drug (Treatment A)
Study: NCT02300688
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 time administration of the reference drug (Treatment B)
Study: NCT00669162
Drug: Casodex and Zoladex (or Lupron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
Study: NCT04983160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01634139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily in the evening
Study: NCT00250263
Drug: (agent for immunotherapy) Staloral
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Alor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily
Study: NCT00250263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily
Study: NCT00862095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every month for 3 months
Study: NCT01906008
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
Study: NCT01906008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
Study: NCT00740831
Drug: PGL4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01830972
Drug: SA-IR 500 mg
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT02319993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
Study: NCT03214588
Drug: TAK-831 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 placebo matching tablets
Study: NCT02020330
Drug: Artemether-lumefantrine 3 days
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
Study: NCT02620137
Drug: Multicentrum® (Pfizer, Spain) 3 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
Study: NCT02620137
Drug: Multicentrum® (Pfizer, Spain) 12 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
Study: NCT02020330
Drug: Artemether-lumefantrine 5 days
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
Study: NCT01395628
Drug: in vitro sensitivity-directed chemotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01895764
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
Study: NCT02624908
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
Study: NCT02849951
Drug: LT-02
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
Study: NCT01103843
Drug: Maintenance Dose Arm
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
Study: NCT00380497
Drug: PEG-Lyte®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00380497
Drug: Pico-Salax®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01366209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent given as 3 divided doses 3 times per day.
Study: NCT01397578
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous infusion
Study: NCT01753791
Drug: 80 mg PF-06473871
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of PF-06473871 or placebo
Study: NCT01753791
Drug: 160 mg PF-06473871
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of PF-06473871 or placebo
Study: NCT01753791
Drug: 320 mg PF-06473871
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of PF-06473871 or placebo
Study: NCT00809705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc once weekly for 12 weeks
Study: NCT03073798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg of placebo is used